reported elevated GDF15 levels in serous ovarian tumors with low malignant potential and proposed an essential role of this factor in terminal differentiation and restricting cellular proliferation.49 This provides evidence that GDF15 might serve as a novel target for the sensitization of ovarian cancer patients to carboplatin treatment. The gene discussed is GDF15; the disease is ovarian cancer.